These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1363335)

  • 1. Neuroleptic treatment is an unlikely cause of elevated dopamine in thalamus of schizophrenic subjects.
    Oke AF; Putz C; Adams RN; Bird ED
    Psychiatry Res; 1992 Dec; 45(4):203-8. PubMed ID: 1363335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated dopamine/norepinephrine ratios in thalami of schizophrenic brains.
    Oke AF; Adams RN; Winblad B; von Knorring L
    Biol Psychiatry; 1988 May; 24(1):79-82. PubMed ID: 3370279
    [No Abstract]   [Full Text] [Related]  

  • 3. The volume of the mediodorsal thalamic nucleus in treated and untreated schizophrenics.
    Pakkenberg B
    Schizophr Res; 1992 Jul; 7(2):95-100. PubMed ID: 1355358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases.
    Seeman P; Bzowej NH; Guan HC; Bergeron C; Reynolds GP; Bird ED; Riederer P; Jellinger K; Tourtellotte WW
    Neuropsychopharmacology; 1987 Dec; 1(1):5-15. PubMed ID: 2908095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroleptic drug effect on plasma dopamine-beta-hydroxylase in schizophrenia.
    Baron M; Gruen R; Levitt M; Kane J
    Neuropsychobiology; 1982; 8(6):312-4. PubMed ID: 6131392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients.
    Gattaz WF; Riederer P; Reynolds GP; Gattaz D; Beckmann H
    Psychiatry Res; 1983 Apr; 8(4):243-50. PubMed ID: 6576391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of schizophrenic patients relapsed on and off medication.
    Bartkó G; Mayláth E; Herczeg I
    Psychiatry Res; 1987 Nov; 22(3):221-7. PubMed ID: 2893403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low serum neuroleptic levels predict relapse in schizophrenic patients.
    Brown WA; Laughren T; Chisholm E; Williams BW
    Arch Gen Psychiatry; 1982 Sep; 39(9):998-1000. PubMed ID: 6126172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
    Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
    Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal neuroleptic/dopamine receptors in schizophrenia.
    Lee T; Seeman P
    Adv Biochem Psychopharmacol; 1980; 21():435-42. PubMed ID: 6103653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of midline thalamic nuclei by antipsychotic drugs.
    Cohen BM; Wan W; Froimowitz MP; Ennulat DJ; Cherkerzian S; Konieczna H
    Psychopharmacology (Berl); 1998 Jan; 135(1):37-43. PubMed ID: 9489932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
    Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL
    Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroleptic-induced reductions in serum dopamine-beta-hydroxylase in schizophrenia.
    Goodnick PJ; Tong C; Duncavage MB; Meltzer HY
    Biol Psychiatry; 1983 Dec; 18(12):1485-8. PubMed ID: 6140962
    [No Abstract]   [Full Text] [Related]  

  • 14. Pathophysiology of schizophrenia and the role of newer antipsychotics.
    Risch SC
    Pharmacotherapy; 1996; 16(1 Pt 2):11-4. PubMed ID: 8778681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
    Nagaoka S; Iwamoto N; Arai H
    Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerance to the prolactin-elevating effect of neuroleptics.
    Brown WA; Laughren TP
    Psychiatry Res; 1981 Dec; 5(3):317-22. PubMed ID: 6119716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system.
    Chouinard G; Annable L; Jones BD; Collu R
    Acta Psychiatr Scand; 1981 Nov; 64(5):353-62. PubMed ID: 6126066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A longitudinal study of cerebrospinal fluid angiotensin-converting enzyme in neuroleptic-treated schizophrenia.
    Wahlbeck K; Ahokas A; Nikkilä H; Miettinen K; Rimón R
    Prog Neuropsychopharmacol Biol Psychiatry; 1997 May; 21(4):591-9. PubMed ID: 9194142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet dopamine uptake in Huntington's chorea and Gilles de la Tourette's syndrome: effect of haloperidol.
    Butterworth RF; Gonce M; Barbeau A
    Can J Neurol Sci; 1977 Nov; 4(4):285-8. PubMed ID: 145893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.